MedTrace Logo

Treating Acute Pancreatitis With Dabigatran, a Pilot Study

NCT03807856 · Status: TERMINATED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 2

Last updated 2022-09-01

No results posted yet for this study

Summary

Researchers are studying the safety and efficacy of Dabigatran in the treatment of acute pancreatitis.

Conditions

Interventions

DRUG

Dabigatran Etexilate Mesylate

Dabigatran 150mg BID for 3 days

OTHER

Standard of Care

Daily vital signs, lab work and one outpatient clinic visit

Sponsors & Collaborators

Principal Investigators

  • Yan Bi, MD, PhD · Mayo Clinic

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-06-24
Primary Completion
2020-07-23
Completion
2020-07-23
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03807856 on ClinicalTrials.gov